Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
hereditary angioedema
Biotech
Kaken strengthens late-stage HAE portfolio with $32M Astria deal
Kaken Pharmaceutical is paying $16 million upfront for the Japanese rights to Astria Therapeutics’ phase 3-stage hereditary angioedema drug.
James Waldron
Aug 6, 2025 10:21am
FDA's 'heavy workload' blamed for delaying KalVista's PDUFA date
Jun 16, 2025 4:33am
KalVista sells Japanese rights for HAE drug to Kaken
Apr 8, 2025 8:35am
Poseida gene therapy reduces kallikrein protein levels in mice
Oct 24, 2024 1:20pm
Intellia links in vivo CRISPR therapy to 81% drop in HAE attacks
Oct 24, 2024 8:55am
Pharming uproots angioedema gene therapy collab with Orchard
May 8, 2024 6:15am
